Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Mar;19(1):82-6.
doi: 10.3350/cmh.2013.19.1.82. Epub 2013 Mar 25.

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B

Eun Hye Kim  1 , Hana Park, Kun Ho Lee, Sang Hoon Ahn, Seung-Min Kim, Kwang-Hyub Han
Affiliations
Case Reports

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B

Eun Hye Kim et al. Clin Mol Hepatol. 2013 Mar.

Abstract

Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). Clinical trials have shown that telbivudine has a more potent and sustained antiviral activity with a lower frequency of viral resistance than lamivudine. Although there are several reports concerning the safety profile of telbivudine, most adverse events are described as mild and transient in nature. Here we report two cases of telbivudine-induced myopathy in patients with chronic hepatitis B who were siblings.

Keywords: Adverse effects; Hepatitis B; Myopathy; Telbivudine.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts to disclose.

Figures

Figure 1
Figure 1
Electromyographic findings of one of the patients (case 1). Mild, sharp, positive waves with small, brief amplitudes, and polyphasic myopathic motor unit action potentials with full interference patterns were recorded in the right biceps brachii muscles.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lai CL, Yuen MF. Chronic hepatitis B--new goals, new treatment. N Engl J Med. 2008;359:2488–2491. - PubMed
    1. Kim SS, Cheong JY, Cho SW. Current nucleos(t)ide analogue therapy for chronic hepatitis B. Gut Liver. 2011;5:278–287. - PMC - PubMed
    1. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010. - PubMed
    1. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800–807. - PubMed
    1. Jeong ID, Park NH, Kim BC, Park JH, Seo KW, Kim DH, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases. Korean J Hepatol. 2003;9:69–78. - PubMed

Publication types

LinkOut - more resources